Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | IDE | P14735 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | RIN1 | Q13671 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | HLCS | P50747 | 6/20 | 0.69 |
| ▸ | CA12 | O43570 | 7/20 | 0.56 |
| ▸ | CA1 | P00915 | 7/20 | 0.56 |
| ▸ | CA2 | P00918 | 7/20 | 0.56 |
| ▸ | CA9 | Q16790 | 7/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biotin SCHEMBL826595 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL5376391 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL36572 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL9841217 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL410686 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL59420 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL23055065 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL21981206 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL22943835 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL3384633 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340591-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | ANYGEN CO LTD (KR) | 2025-11-06 | — | — | US | disclosed |
| CN-117616034-A | Composition for preventing or treating inflammatory bowel disease containing novel compounds | 安尼根有限公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-4317171-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | Anygen Co., Ltd. (KR) | 2024-02-07 | — | — | EP | disclosed |
| US-20230212222-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | ANYGEN CO., LTD. (KR) | 2023-07-06 | — | — | US | disclosed |
| US-20230159661-A1 | T CELL REDIRECTING BISPECIFIC ANTIBODIES FOR THE TREATMENT OF EGFR POSITIVE CANCERS | Ichnos Sciences SA (CH) | 2023-05-25 | — | — | US | disclosed |
| WO-2023038464-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | 애니젠 주식회사 | 2023-03-16 | — | — | WO | disclosed |
| EP-4119570-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | Anygen Co., Ltd. (KR) | 2023-01-18 | — | — | EP | disclosed |
| EP-3615571-A1 | T CELL REDIRECTING BISPECIFIC ANTIBODIES FOR THE TREATMENT OF EGFR POSITIVE CANCERS | Ichnos Sciences SA (CH) | 2020-03-04 | — | — | EP | disclosed |
| CN-110831968-A | T cell redirecting bispecific antibodies for the treatment of EGFR-positive cancer | 伊克诺斯科学公司 | 2020-02-21 | — | — | CN | disclosed |
| WO-2018197502-A1 | T CELL REDIRECTING BISPECIFIC ANTIBODIES FOR THE TREATMENT OF EGFR POSITIVE CANCERS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-11-01 | — | — | WO | disclosed |
| CN-1420173-A | High-temp. resistant biotin synthetase gene, polypeptide coded therewith and preparing method thereof | HUADA GENE RES & DEV CT HANGZH (CN) | 2003-05-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340591-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | GPR39, FABP2, GPR119 | TDP1 4831/4885MEN1 4772/4885ABL1 4137/4885 |
| US-20230212222-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | GPR119, GPR39, FABP4 | TDP1 4730/4885MEN1 4708/4885ABL1 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.